However, the CD8+ T cell differentiation trajectory in NSCLC could hamper the sensitivity of CD8+ T cells to immune checkpoint therapy, potentially leading to ICB failure in T cell-infiltrated NSCLC19. This evidence concerns the gene CD8A and non-small cell lung carcinoma.